What is the CHA₂DS₂-VASc score?

It is a clinical prediction rule used to estimate stroke risk in patients with atrial fibrillation. Each letter represents a risk factor: Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke/TIA (doubled), Vascular disease, Age 65–74, and Sex category (female). Scores range from 0 to 9.

When should anticoagulation be started?

Guidelines generally recommend anticoagulation for men with a score ≥ 1 and women with a score ≥ 2. A score of 0 in men or 1 in women (where the only point is sex) is considered low risk and may not require anticoagulation. Always consult current guidelines and clinical judgment.

How is CHA₂DS₂-VASc different from CHADS₂?

CHA₂DS₂-VASc is an expanded version of the older CHADS₂ score. It adds vascular disease, age 65–74, and female sex as additional risk factors. It is better at identifying truly low-risk patients who may not need anticoagulation.

Why is female sex a risk factor?

Female sex is included as a risk modifier because studies show women with atrial fibrillation have a higher relative stroke risk than men, particularly at older ages. However, female sex alone (score of 1) is generally not considered an indication for anticoagulation in the absence of other risk factors.

What is the annual stroke risk for each score?

Score 0: 0.2%. Score 1: 0.6%. Score 2: 2.2%. Score 3: 3.2%. Score 4: 4.8%. Score 5: 7.2%. Score 6: 9.7%. Score 7: 11.2%. Score 8: 10.8%. Score 9: 12.2%. These rates are from the original Lip et al. validation study.

Is aspirin an alternative to anticoagulation?

No. Current ESC and AHA guidelines recommend against aspirin for stroke prevention in AFib. Aspirin provides minimal protection against ischemic stroke while still carrying bleeding risk. The options are anticoagulation or no antithrombotic therapy.

Which anticoagulant is best?

For non-valvular AFib, direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin per 2023 guidelines. DOACs have favorable safety profiles, fixed dosing, no INR monitoring, and fewer drug/food interactions.

Does paroxysmal AFib have lower stroke risk?

No. Studies show paroxysmal (intermittent), persistent, and permanent AFib carry similar thromboembolic risk. CHA₂DS₂-VASc applies regardless of AFib pattern. Even a single documented AFib episode warrants risk stratification.

How is heart failure defined for this score?

Heart failure scores a point if there is documented moderate-to-severe LV systolic dysfunction (EF ≤40%), clinical heart failure (signs/symptoms), or recent heart failure hospitalization. Preserved EF heart failure (HFpEF) may also qualify if symptomatic.

What counts as vascular disease?

Vascular disease includes prior MI, peripheral artery disease (PAD), complex aortic plaque, or carotid stenosis. Any documented atherosclerotic disease adds 1 point. Coronary artery disease on imaging counts even without prior MI.

Should I calculate this for atrial flutter?

Yes. Atrial flutter carries similar thromboembolic risk to atrial fibrillation. Most guidelines recommend using CHA₂DS₂-VASc for anticoagulation decisions in both conditions, especially for typical atrial flutter.

What if I have both high stroke and bleeding risk?

High bleeding risk ([HAS-BLED](/tools/has-bled) ≥3) does not contraindicate anticoagulation. Studies show that even high-risk patients derive net clinical benefit from anticoagulation. Focus on modifying reversible bleeding risk factors while continuing anticoagulation.

Is this score used for other conditions?

CHA₂DS₂-VASc was designed for AFib. It should not be used for risk stratification in mechanical heart valves (always anticoagulate), DVT/PE (different treatment protocols), or primary stroke prevention without AFib.

How often should I recalculate my score?

Reassess annually or whenever risk factors change. New diagnoses (hypertension, diabetes, heart failure, vascular disease), birthday crossing age thresholds (65, 75), or thromboembolic events all warrant recalculation and potential management changes.

What is the CHA₂DS₂-VASc-RAF score?

Some researchers have proposed modifications adding renal dysfunction, abnormal liver function, and other factors. However, the standard CHA₂DS₂-VASc remains the guideline-recommended tool. Modified versions have not been broadly adopted or validated.

Online Medical Tools — CHA₂DS₂-VASc Score

Printed on 8/14/2026

For informational purposes only. This is not medical advice.

Cardiology

CHA₂DS₂-VASc Score

The CHA₂DS₂-VASc score is the most widely used clinical prediction tool for estimating stroke risk in patients with non-valvular atrial fibrillation. It helps clinicians decide whether anticoagulation therapy is warranted by scoring risk factors including heart failure, hypertension, age, diabetes, prior stroke, vascular disease, and sex.

Formula: Score = CHF(1) + Hypertension(1) + Age≥75(2) + Diabetes(1) + Stroke(2) + Vascular(1) + Age 65–74(1) + Female(1)

Congestive Heart Failure

Hypertension

Age ≥ 75

Diabetes Mellitus

Stroke/TIA/Thromboembolism

Vascular Disease

Age 65–74

Sex Category (Female)

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Answer each risk factor question

Select yes or no for each of the eight risk factors. Some factors carry 2 points (age ≥75, prior stroke/TIA) while others carry 1 point.

Calculate your total score

The calculator sums your points, producing a score from 0 to 9. Higher scores indicate greater annual stroke risk from atrial fibrillation.

Interpret anticoagulation guidance

Compare your score to guideline thresholds. Men with scores ≥1 and women with scores ≥2 typically warrant anticoagulation per ESC/AHA guidelines.

Who Uses the CHA₂DS₂-VASc Score

New AFib Diagnosis

Cardiologists, internists

At the time of new atrial fibrillation diagnosis, calculate the score to determine whether anticoagulation should be initiated immediately or deferred.

Anticoagulation Decision

Primary care physicians

Use alongside [HAS-BLED](/tools/has-bled) to weigh stroke prevention benefit against bleeding risk, guiding the shared decision-making conversation with patients.

Hospital Admission Review

Hospitalists, clinical pharmacists

Reassess stroke risk during hospital admissions to ensure appropriate anticoagulation is prescribed before discharge.

Annual Risk Reassessment

Follow-up clinic visits

Recalculate yearly as risk factors change — new hypertension, diabetes, or vascular disease diagnosis increases the score and may change management. Also reassess bleeding risk with [HAS-BLED](/tools/has-bled) annually.

Pre-Procedure Evaluation

Surgeons, proceduralists

Quantify stroke risk to plan perioperative anticoagulation bridging or guide decisions about procedure timing in AFib patients.

Patient Education

Patients with AFib

Understand your personal stroke risk and why your doctor recommends anticoagulation, empowering informed participation in treatment decisions.

Pro Tips

Female sex alone is not an indication for anticoagulation

ESC 2020 guidelines clarify that female sex is a risk modifier, not an independent risk factor. A woman with a score of 1 (only from sex category) should be treated the same as a man with a score of 0 — no anticoagulation recommended.

Always pair with HAS-BLED

High stroke risk doesn't automatically mean anticoagulate. Always [calculate HAS-BLED](/tools/has-bled) to quantify bleeding risk. Even with high HAS-BLED scores, anticoagulation usually still provides net benefit, but it guides closer monitoring.

Prior stroke/TIA is the strongest risk factor

A history of stroke, TIA, or systemic embolism automatically adds 2 points and typically mandates anticoagulation regardless of other factors. This represents secondary prevention, not just primary prevention.

Valvular AFib requires anticoagulation regardless of score

CHA₂DS₂-VASc is for non-valvular AFib. Patients with mitral stenosis or mechanical heart valves need anticoagulation (often warfarin, not DOACs) regardless of their score.

DOACs are preferred over warfarin for most patients

2023 ESC/AHA guidelines recommend direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin for non-valvular AFib due to better safety profiles and no INR monitoring requirement.

Hypertension means treated or uncontrolled BP ≥140/90

Score hypertension as present if the patient has a diagnosis requiring treatment OR has untreated blood pressure consistently ≥140/90 mmHg. Well-controlled hypertension still counts.

Vascular disease includes PAD and aortic plaque

Vascular disease isn't just prior MI — it includes peripheral artery disease, aortic atherosclerosis, and carotid stenosis. Any documented atherosclerotic disease adds 1 point. Use [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk) to assess cardiovascular risk in patients without established disease.

Age categories don't double-count

Select either age 65-74 OR age ≥75, not both. A 78-year-old gets 2 points (for ≥75), not 3 points. The calculator handles this automatically.

Heart failure requires objective evidence

Score CHF as present if there's documented moderate-to-severe LV systolic dysfunction (EF <40%) or recent heart failure hospitalization. Asymptomatic mild diastolic dysfunction alone is not typically counted.

Score of 0 in men is truly low risk

Men with CHA₂DS₂-VASc of 0 have an annual stroke risk of approximately 0.2%. Guidelines support withholding anticoagulation, though aspirin is no longer recommended as an alternative (provides no benefit with bleeding risk).

Common Questions About Your Results

Evidence-Based Methodology

CHA₂DS₂-VASc was introduced by Lip et al. (2010) as an improvement over CHADS₂ for better identification of low-risk patients. It is endorsed by ESC (2020), AHA/ACC/HRS (2023), and NICE guidelines for stroke risk stratification in non-valvular AFib. Annual stroke rates by score are derived from the original validation cohort and subsequent large registry studies.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Your CHA₂DS₂-VASc score ranges from 0 to 9 and directly corresponds to an annual stroke risk. A score of 0 in men (or 1 in women where the only point is for female sex) indicates low risk — annual stroke rate is approximately 0.2–0.3%, and anticoagulation is generally not recommended. A score of 1 in men or 2 in women places you in a moderate-risk category where anticoagulation should be considered. A score of 2 or higher in men (3+ in women) carries a clearly elevated stroke risk (roughly 2–15% per year depending on the score) and anticoagulation is generally recommended.

The score should always be interpreted alongside the [HAS-BLED bleeding risk score](/tools/has-bled) to weigh the benefit of stroke prevention against the risk of major bleeding from anticoagulation therapy.

When to Use This Tool

Use this calculator whenever assessing the need for anticoagulation in a patient with non-valvular atrial fibrillation or atrial flutter. It is the standard risk stratification tool recommended by the ESC, AHA/ACC, and most international cardiology guidelines.

It is particularly useful at the time of a new atrial fibrillation diagnosis, during follow-up visits when risk factors may have changed (e.g., new diagnosis of diabetes or vascular disease), and when re-evaluating anticoagulation decisions in patients whose clinical status has evolved.

Limitations

The CHA₂DS₂-VASc score was designed for non-valvular atrial fibrillation. Patients with valvular AF (especially mitral stenosis or mechanical heart valves) require anticoagulation regardless of their score and should not rely on this tool for decision-making.

The score treats all risk factors as binary (present or absent) and does not weight severity. For example, well-controlled hypertension and refractory hypertension receive the same point. Similarly, a remote TIA and a recent disabling stroke both score 2 points.

Female sex alone (score of 1) is considered a risk modifier rather than an independent risk factor — guidelines do not recommend anticoagulation for women whose only point is sex category. The score also does not account for certain emerging risk factors such as chronic kidney disease, obesity, or obstructive sleep apnea, which may independently increase stroke risk in atrial fibrillation.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Sources

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools